ENVB News
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
Enveric Biosciences posts positive preclinical data for EB-003, showing favorable absorption and safety for psychiatric therapies.read more...
Benzinga
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
Enveric Biosciences posts positive preclinical data for EB-003, showing favorable absorption and safety for psychiatric therapies.read more...
Benzinga
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced positive results from recently completed IND-enabling in vitro Absorption...
Business Wire
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark...
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the...
Business Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a...
Business Wire
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.read more...
Benzinga
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing...
Business Wire
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for...
Business Wire
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held...
Business Wire
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June...
Business Wire